Home page Random article About FAQ Contact us Donate
Contribute
New article Recent changes Chopping block Developers
Tools
Documentation Bib2Yaml

When does patient need outweigh scientific rigor when approving experimental drugs?

@FxB26E4E

Meta
Domain: @F
Commit: 6
»

Status: head
Author: Ender
Date: 25 June 2021, 12:59 (UTC)

is a question related to the recent decision by the FDA to grant approval to an experimental Alzheimer’s drug, Aducanumab, despite significant opposition from the scientific community [Ix4]. When confronted with an intractable, widespread disease, when–if ever–is it acceptable to prematurely grant approval for a questionably effective treatment?

Patient need [edit]

Alzheimer’s is a devastating disease with no known cure, and has had no new medications approved for its treatment since 2003. Consequently, there is a significant amount of despair and hopelessness associated with its diagnosis [Tx4].